Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine-Reference-Cited by-同舟云学术

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

Published:2018-05-15 Issue:19 Volume:319 Page:1999
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Dodick David W.¹,Silberstein Stephen D.²,Bigal Marcelo E.³,Yeung Paul P.³,Goadsby Peter J.⁴,Blankenbiller Tricia³,Grozinski-Wolff Melissa³,Yang Ronghua³,Ma Yuju³,Aycardi Ernesto³

Affiliation:

1. Mayo Clinic Arizona, Phoenix

2. Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania

3. Teva Pharmaceuticals, Frazer, Pennsylvania

4. NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, London, England

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 411 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching of monoclonal antibodies against the calcitonin gene-related peptide or its receptor in migraine. Results from a Spanish Cohort;Neurology Perspectives;2024-10

2. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study;European Journal of Neurology;2024-09-04

3. Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial;Headache: The Journal of Head and Face Pain;2024-09-02

4. Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA;Brain Sciences;2024-08-30

5. Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies;CNS Drugs;2024-08-22